证券代码：300452 证券简称：山河药辅 公告编号：2023-065 债券代码：123199 债券简称：山河转债 关于"山河转债"预计满足转股价格修正条件的提示性公 告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 一、可转换公司债券基本情况 经中国证券监督管理委员会《关于同意安徽山河药用辅料股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕268 号）同意注 册，公司于 2023 年 6 月 12 日向不特定对象发行可转换公司债券（以下简称"可 转债"）3,200,000 张，每张面值为人民币 100 元，发行总额为人民币 证券代码：300452，证券简称：山河药辅 债券代码：123199，转债简称：山河转债 转股价格：18.25 元/股 转股时间：为 2023 年 12 月 16 日至 2029 年 6 月 11 日 根据《深圳证券交易所上市公司自律监管指引第 15 号——可转换公司债券》 规定，"上市公司应当在预计触发转股价格修正条件的 5 个交易日前及时 披露提示性公告。"自 2023 年 10 月 16 日至 2023 年 10 月 ...

Financial Performance - Revenue for Q3 2023 reached ¥187,411,687.03, an increase of 13.43% year-over-year, and cumulative revenue for the year-to-date was ¥640,355,017.44, up 21.93% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥35,201,835.29, representing a 23.65% increase year-over-year, with year-to-date net profit at ¥123,531,091.50, up 30.54%[4] - Basic and diluted earnings per share for Q3 2023 were both ¥0.15, reflecting a 25.00% increase compared to the same quarter last year[4] - The net profit for Q3 2023 was CNY 125,689,496.75, an increase of 34.4% compared to CNY 93,461,300.05 in Q3 2022[25] - Operating profit reached CNY 141,682,634.11, up from CNY 105,348,970.98, reflecting a growth of 34.5% year-over-year[25] - The total comprehensive income for the period was CNY 125,689,496.75, compared to CNY 93,461,300.05 in the previous year, indicating a growth of 34.4%[26] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥1,482,423,518.34, a 25.57% increase from the end of the previous year[4] - As of September 30, 2023, total assets reached CNY 1,482,423,518.34, an increase from CNY 1,180,550,962.11 at the beginning of the year, representing a growth of approximately 25.6%[22] - The company's total liabilities as of September 30, 2023, amounted to CNY 582,139,890.22, compared to CNY 391,933,246.05 at the beginning of the year, marking an increase of about 48.5%[22] - Total current assets increased to CNY 880,185,319.57 from CNY 631,320,405.29, reflecting a growth of approximately 39.3%[21] - The company’s non-current assets totaled CNY 602,238,198.77, up from CNY 549,230,556.82, representing an increase of approximately 9.7%[22] Cash Flow - The cash flow from operating activities showed a decline of 17.30% year-to-date, totaling ¥47,218,824.42[4] - Cash flow from operating activities generated CNY 47,218,824.42, down from CNY 57,097,827.18 in the same period last year[28] - Net cash flow from investment activities for the year-to-date was -317.1869 million yuan, a decrease of 654.64% year-on-year, primarily due to increased cash payments for purchasing financial products and fixed asset construction[11] - Net cash flow from financing activities for the year-to-date was 236.9416 million yuan, an increase of 510.81% year-on-year, mainly due to funds raised from convertible bonds[11] - The cash and cash equivalents at the end of the period were CNY 89,701,241.43, compared to CNY 83,437,409.98 at the end of Q3 2022[28] - The company’s cash and cash equivalents decreased to CNY 116,515,129.94 from CNY 150,119,055.59, a reduction of about 22.4%[20] Investments and Construction - The company reported a significant increase in trading financial assets, which rose by 131.03% to ¥495,710,100.00, primarily due to the purchase of financial products[7] - The company’s investment income decreased by 35.02% year-to-date, totaling ¥3,862,200.00, mainly due to reduced returns from matured financial products[9] - The company is continuing the construction of a new pharmaceutical auxiliary production base, which has led to a 44.00% increase in construction in progress, totaling ¥222,607,700.00[7] - The new pharmaceutical excipient production base project has entered the trial production phase as of September 2023, indicating progress in market expansion efforts[18] - The company reported a significant increase in investment activities, with cash outflow for investments reaching CNY 678,312,000.00, compared to CNY 318,750,000.00 in the previous year[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,855[12] - The largest shareholder, Yin Zhenglong, holds 26.89% of shares, totaling 63,057,454 shares[13] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 11.20% of shares, totaling 26,254,059 shares[13] - The top ten shareholders include various natural persons and investment funds, with the smallest holding being 0.59%[14] - The company has a total of 48,095,265 restricted shares, with 62,400 shares released during the period[17] - The company has implemented a three-phase release plan for restricted shares, starting 12 months after the completion of the grant registration[17] Research and Development - Research and development expenses increased to CNY 30,674,826.71, a rise of 27.5% from CNY 24,076,821.87 in the previous year[25] - In Q3 2023, the company launched 3 new products registered with CDE, enhancing its high-end product development capabilities[18] Miscellaneous - The company did not undergo an audit for the Q3 report[30] - The impact of exchange rate fluctuations on cash for the year-to-date was 22,200 yuan, a decrease of 98.88% year-on-year, primarily due to reduced foreign exchange gains from currency fluctuations[11] - Minority shareholder profit for the year-to-date reached 2.1584 million yuan, an increase of 285.07% year-on-year, mainly due to reduced losses from the controlling company Qufu Tianli[11] - The company’s inventory decreased to CNY 73,642,045.66 from CNY 91,197,744.75, a decline of approximately 19.2%[21]

证券代码：300452 证券简称：山河药辅 公告编号：2023-064 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于使用部分暂时闲置募集资金购买的理财产品到期赎回 及继续购买理财产品的进展公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）于 2023 年7 月4 日召开了第五届董事会第十五次会议和第五届监事会第十五 次会议，审议通过了《关于使用部分暂时闲置募集资金进行现金管理 的议案》，公司拟使用公司向不特定对象发行可转换债券募集资金不 超过12,000 万元的暂时闲置募集资金进行现金管理。在上述额度内， 资金可以滚动使用，期限为使用期限自公司第五届第十五次董事会审 议通过之日起 12 个月内有效。 近日，公司前次使用暂时闲置募集资金购买的理财产品已有部分 到期赎回，公司继续使用暂时闲置募集资金购买理财产品，具体情况 如下： 一、到期赎回的理财产品情况 2023 年 7 月 12 日，公司使用闲置募集资金 2500 万元购买了 交通银行"蕴通财富"定期型结构性存款产品，具体内容详见公司刊 ...

证券代码：300452 证券简称：山河药辅 公告编号：2023-062 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称 "公司"）于 202 3 年 9 月 25 日收到公司保荐机构国元证券股份有限公司（以下简 称"国元证券"）《关于变更安徽山河药用辅料股份有限公司持续督 导工作保荐代表人的函》。国元证券作为公司 2023 年向不特定对象 发行可转换公司债券的保荐机构和持续督导机构，指定朱焱武先生、 杨凯强先生担任公司持续督导保荐代表人，现因朱焱武先生工作调整， 为保证公司持续督导工作的有序进行，国元证券决定刘民昊先生接替 朱焱武先生的持续督导工作，继续履行保荐职责。 2023 年 9 月 25 日 附件： 公司董事会对朱焱武先生在公司 2023 年向不特定对象发行可转 换公司债券以及持续督导期间所做出的贡献表示衷心的感谢。 刘民昊先生的简历详见附件。 特此公告。 安徽山河药用辅料股份有限公司 董事会 本次变更后，负责公司持续督 ...

证券代码：300452 证券简称：山河药辅 公告编号：2023-061 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 关于公司新型药用辅料系列生产基地一期项目试生产 的公告 本项目建成后将显著提升公司核心品种的生产能力，进一步提升 公司产品的规模优势，有助于巩固并扩大公司在新型药用辅料领域的 市场份额和市场地位，符合公司的中长期发展规划。 鉴于目前该项目仅进入试生产阶段，从试生产到规模化生产、释 放产能尚需一定时间。未来可能存在市场环境变化、竞争加剧、产品 销售价格波动、原材料价格波动等潜在风险。敬请广大投资者注意投 资风险。 一、项目基本情况 "新型药用辅料系列生产基地一期项目"为公司 2023 年度向不 特定性对象发行可转换公司债券募投项目，本项目建设主体为山河药 辅，项目总投资33,500.00 万元，计划使用募集资金21,000.00 万元。 本项目拟扩建年产5,000吨微晶纤维素和年产2,800 吨羟丙甲纤维素 生产线，新建年产 500 吨交联聚维酮和年产 500 吨交联羧甲纤维素钠 和年产 200 吨硬脂富马酸钠生产线。 二、项目进展情况 上述项目现已完成工程主体建设及 ...

投资者关系活动记录表 证券代码:300452 证券简称:山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 | --- | --- | --- | |------------------------|---------------------------|----------------------------------| | | | 编号:2023-005 | | | □特定对象调研 □分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | | 参与安徽辖区上市公司 | 2023年投资者网上集体接待日活动的 | | 参与单位名称及人员姓名 | | | 投资者 时间 2023 年 9 月 12 日 15:30-17:30 上市公司接待人员姓名 董事会秘书、财务总监:刘琦 证券事务代表:姜之舟 地点 "全景•路演天下"(http://rs.p5w.net) 投资者提出的问题及公司回复情况 问题 1:领导你好,公司新项目几日投料试车? 回复:投资者您好,公司新区项目建设已接近尾声,现 在正 ...

证券代码:300452 证券简称:山河药辅 公告编号:2023-060 债券代码:123199 债券简称:山河转债 安徽山河药用辅料股份有限公司 关于参加安徽辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 为进一步加强与投资者的互动交流,安徽山河药用辅料股份有限 公司(以下简称 "公司")将参加由安徽证监局、安徽省上市公司 协会与深圳市全景网络有限公司联合举办的"2023 年安徽辖区上市 公司投资者网上集体接待日"活动,现将相关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演" 网站(https://rs.p5w.net),或关注微信公众号:全景财经,或下 载全景路演 APP, 参与本次互动交流,活动时间为 2023 年 9 月 1 2 日(周二)15:30-17:30。届时公司高管将在线就公司 2023 年半 年度业绩、公司治理、发展战略、经营状况、新项目建设进展等投资 者关心的问题,与投资者进行沟通与交流,欢迎广大投资者踊跃参与! 特此公告。 安徽山河药用辅料股份有限公司 董事会 202 ...

投资者关系活动记录表 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 编号：2023-004 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他（电话交流会） | | | 【中信证券】：陈竹、唐寅灏、韩世通；【西南证券】：杨 | | | 天笑、王彦迪；【光大证券】：曹聪聪；【国金证券】王大 | | | 伟；【东方证券】韩冰；【信达证券】：唐爱金；【民生证 | | | 券】：杜鹏程；【长信基金】：胡梦承；【华夏基金】：袁 | | | 绮蔓；【国华兴益】：范佳锴；【惠升基金】：张政；【广 | | | 发证券】：杨正；【永安国富】：李勇；【中国人保】：田 | | | 垒；【深圳量子基金】：孙哮江；【招商证券】：邱捷铭； | | | 【汇安基金】：周冲；【长盛基金】：张伟光；【北京金百 | | | 镕投资】：马学进；【南银理财】：高梁宇；【国元证券】： | | 参与单位名称及人员姓名 | 马云涛；【中金资管】：柳天慧；【 ...

国元证券股份有限公司 关于安徽山河药用辅料股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐人名称：国元证券股份有限公司 | 被保荐公司简称：山河药辅 | | --- | --- | | 保荐代表人姓名：朱焱武 | 联系电话：0551-62207977 | | 保荐代表人姓名：杨凯强 | 联系电话：0551-62207014 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包 | | | 括但不限于防止关联方占用公司资源的制 | 是 | | 度、募集资金管理制度、内控制度、内部 | | | 审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 1 次，每月查询公司募集资金专户情况 | | （2）公司募集资金项目进展 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥452,943,330.41, representing a 25.83% increase compared to ¥359,974,941.25 in the same period last year[20]. - The net profit attributable to shareholders was ¥88,329,256.21, up 33.51% from ¥66,159,007.20 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥81,829,665.85, reflecting a 38.00% increase from ¥59,296,357.77 in the prior year[20]. - The basic earnings per share increased to ¥0.38, a rise of 35.71% compared to ¥0.28 in the same period last year[20]. - The total assets at the end of the reporting period reached ¥1,481,763,200.08, marking a 25.51% increase from ¥1,180,550,962.11 at the end of the previous year[20]. - The net assets attributable to shareholders were ¥796,737,083.75, which is a 10.27% increase from ¥722,521,885.86 at the end of the last year[20]. - The net cash flow from operating activities was ¥51,322,468.22, down 23.67% from ¥67,238,163.29 in the same period last year[20]. - The weighted average return on equity increased to 11.67%, up from 9.97% in the previous year[20]. - The company reported a significant increase in revenue, with a growth rate of 20% compared to the previous year[32]. - The company reported a net profit of CNY 81.83 million for the first half of 2023, representing a 38% increase compared to the same period last year[165]. - The current ratio improved to 3.06, up 67.21% from the previous year, indicating enhanced liquidity[165]. - The quick ratio also increased to 2.78, reflecting a 78.21% rise year-over-year[165]. Market Position and Industry Outlook - The company operates in the pharmaceutical manufacturing industry, specifically in the field of pharmaceutical excipients, which are crucial components in drug formulations, accounting for over 90% of the drug composition[28]. - The domestic pharmaceutical excipients market is expected to grow significantly due to increased government investment in healthcare and the ongoing promotion of generic drug consistency evaluations[29]. - The pharmaceutical excipients industry in China is projected to maintain stable growth due to factors such as rapid economic growth and an aging population[28]. - The company’s products are primarily used by pharmaceutical companies but are also applicable in the health supplement and food industries[30]. - The international trend of pharmaceutical industry chain restructuring is expected to benefit the company, as it positions itself as a key player in the global pharmaceutical excipients market[29]. - The company has established a large marketing network with over 2,700 long-term clients across more than 30 provinces and regions in China, and exports to various countries including Germany, the UK, and the US[46]. Product Development and Innovation - The company has developed a diverse product line, including 41 products that have received registration numbers from the CDE, and several products have been awarded as high-tech products in Anhui Province[31]. - Key products include microcrystalline cellulose, hydroxypropyl methylcellulose, and sodium carboxymethyl starch, which have been recognized as excellent products in the pharmaceutical excipients industry[30]. - New product development includes the introduction of a novel excipient that enhances drug stability, expected to launch in Q4 2023[35]. - The company has established a strong technical foundation and R&D experience, enabling it to innovate and adapt to market changes effectively[31]. - Research and development expenses rose by 30.08% to ¥22,230,727.10, up from ¥17,089,615.19, indicating a strong commitment to innovation[50]. Strategic Initiatives and Future Plans - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has set a future outlook with a revenue guidance of $150 million for the next quarter, representing a 10% increase year-over-year[34]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2024[32]. - A strategic acquisition of a local supplier is anticipated to enhance supply chain efficiency and reduce costs by 5%[33]. - The company is implementing new strategies to improve production efficiency, aiming for a 30% reduction in production time[34]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[179]. Environmental Responsibility and Compliance - The company has implemented strict environmental protection measures in accordance with national standards and regulations[98]. - The company has consistently reported compliance with environmental standards, with no instances of exceeding discharge limits[99]. - The company has a designated emergency response plan for environmental incidents, which has been filed with the local environmental bureau[104]. - The company has invested over 3 million yuan in environmental protection facilities in the first half of 2023, installing 8 sets of online monitoring equipment to ensure pollutant discharge meets national standards[105]. - The company has not faced any administrative penalties for environmental issues during the reporting period[105]. Risk Factors - The company faces risks related to raw material price fluctuations, quality control, intensified competition, and safety production[4]. - The company faces risks related to the fluctuation of raw material prices, which could impact production costs and profit margins[81]. - The company acknowledges potential risks associated with the handling of flammable and explosive materials[84]. - The company has implemented a dual prevention mechanism for safety production risks, including regular safety training and the establishment of a dedicated safety department[85]. Corporate Governance and Shareholder Matters - The company has not made any changes to its board of directors or senior management during the reporting period[90]. - The company has not received any objections regarding its 2020 stock incentive plan, which was approved by the shareholders[92]. - The company has implemented a stock incentive plan that includes a lock-up period for executives[144]. - The total number of shares before the change was 234,522,691, which decreased to 234,460,291 after the repurchase and cancellation of 62,400 restricted shares[140]. - The company has not engaged in any related party transactions during the reporting period[119]. Financial Management and Investments - The company successfully issued convertible bonds worth 320 million yuan, raising 316 million yuan after deducting issuance costs[40]. - The total investment amount for the reporting period was ¥54,765,943.24, representing a 116.66% increase compared to the previous year's investment of ¥25,277,909.17[61]. - The company has established special accounts for the management of raised funds to protect investor interests[67]. - The company reported a total of 23,031.2 million CNY in entrusted financial management, with an outstanding balance of 20,030 million CNY[74]. - The company has not made any significant asset or equity sales during the reporting period[76][77].